WELCOME TO The Biotechnology REPORT
Newsletter | Member Login | Signup
Home > Companies > Leiden University Medical Center
Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...
Conference
Webinar
BioSpectrum Asia | April 13, 2020
South Korea based Samsung Biologics and US based Vir Biotechnology, Inc. have announced a manufacturing agreement under which Samsung Biologics will perform large scale manufacturing services Vir's SARS-CoV-2 monoclonal antibody (mAb) program. Vir's lead SRS-CoV-2 mAb development candidates, VIR-7831 and VIR-7832, have demonstrated high affinity for the SARS-CoV-2 spike protein and are highly potent in neutralizing SARS-CoV-2 in live-virus cellular assays. Vir plans to proceed directly i...
DIAGNOSTICS
Provectus Algae | August 28, 2021
Provectus Algae, an Australian biotechnology platform company specialising in the biomanufacturing of high-value compounds for a wide array of industries using microalgae, announced they will be expanding into an additional large-scale manufacturing facility. “Since closing our seed round last year, we have been in full swing growing the team, developing products and building capacity with our proprietary production system. We are now in a strong position as we push into thi...
INDUSTRIAL IMPACT, MEDICAL
Celularity | January 17, 2023
Celularity Inc., a biotechnology firm based in the United States that develops placental-derived allogenic cell treatments and biomaterials, and CH Trading Group LLC, an international import, export, and trading corporation, have agreed to an exclusive territorial distribution agreement. CH Trading Group will serve as the exclusive territorial distributor for halal-certified products previously announced by Celularity in over 100 countries. The product distribution agreement for...
CELL AND GENE THERAPY, INDUSTRIAL IMPACT
Vertex | December 09, 2022
Vertex Pharmaceuticals Incorporated and Entrada Therapeutics, Inc. announced a global collaboration focused on discovering and developing intracellular Endosomal Escape Vehicle therapeutics for myotonic dystrophy type 1. The collaboration includes Entrada’s program for DM1, ENTR-701, which is in late-stage preclinical development. “Vertex’s strategy is to discover and develop transformative medicines for people with serious diseases, and DM1...
MEDICAL
Video
Whitepaper
MEDTECH
Article
CELL AND GENE THERAPY
Keep me plugged in with the best
Join thousands of your peers and receive our weekly newsletter with the latest news, industry events, customer insights, and market intelligence.
Welcome back!
Put your news, events, company, and promotional content in front of thousands of your peers and potential customers.
Not a member yet? Not a problem, Sign Up
Sign up
Sign up to contribute and publish your news, events, brand, and content with the community for FREE